April 4, 2017. Like many public health experts and advocates, we are very concerned about treatments that are marketed and promoted for hangovers that contain either acetaminophen or aspirin.
Read More »On Medical Treatments & Products
NCHR Testimony on Labeling and Misuse of Peroxide-Based Contact Lens Products
March 17, 2017. NCHR feels that the only way to avoid misuse and accidents with peroxide-based contact lens solution is to only make these products available behind the counter.
Read More »NCHR Testimony at the FDA Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee
October 19, 2016. In this testimony, we do not recommend this as the first drug approved for nocturia symptoms, unless there is a clinically meaningful benefit and sufficient safety profile for a clearly indicated population.
Read More »NCHR Position Regarding Anthem Decision that Exondys 51 is Experimental
October 7, 2016. We continue to strongly urge Sarepta to do the studies needed to support their claims that patients benefit from Exondys 51, and in the meanwhile Sarepta should ensure that patients in those studies receive the treatment for free.
Read More »NCHR Testimony at 2016 FDA Workshop on Drugs and Biological Products Used During Lactation
April 28, 2016. More clinical studies are desperately needed to determine the safety of drugs in lactating mothers. When these studies are in the planning stages, be cognizant of enrolling mothers that represent a wide diversity of races, ethnicities, and–when appropriate for the drug–ages.
Read More »